1000053-23-5

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 4-(4-AMINO-2-FLUOROPHENYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE is used as a chemical intermediate for the synthesis of potential drug candidates. Its unique structure, including the presence of a tert-butyl group, an amino group, and a fluorophenyl group, makes it a valuable component in the development of new medications for various medical conditions.
TERT-BUTYL 4-(4-AMINO-2-FLUOROPHENYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE's specific applications and potential uses are subject to ongoing research and development, as its properties and interactions with biological systems are further explored. Its role in the pharmaceutical industry is crucial for the advancement of novel therapeutic agents that address unmet medical needs.

InChI:InChI=1S/C15H22FN3O2/c1-15(2,3)21-14(20)19-8-6-18(7-9-19)13-5-4-11(17)10-12(13)16/h4-5,10H,6-9,17H2,1-3H3

Upstream product

• 13035-19-3 4-aminopiperidine 
• 392660-18-3 3-fluoro-4-((4-BOC-amino)piperidino)nitrobenzene 
• 952901-82-5 [3-fluoro-4-(4-aminopiperidino)]nitrobenzene 
• 369-34-6 3,4-difluoronitrobenzene 

Downstream Products

• 1229016-85-6 2-[3-fluoro-4-(4-BOC-aminopiperidino)phenylamino]-6-chloro-3-nitropyridine 
• 1229015-93-3 2-{[3-fluoro-4-(4-aminopiperidino)]phenyl-amino}-6-(methylamino)-3-nitropyridine 
• 1229016-96-9 2-{3-fluoro-4-[(4-BOC-amino)-piperidino]phenylamino}-6-(methylamino)-3-nitropyridine 
• 1000054-09-0 (1-{4-[5-chloro-2-(2-methoxyethoxymethoxy)benzoylamino]-2-fluorophenyl}piperidin-4-yl)carbamic acid tert-butyl ester 
• 1000054-72-7 {1-[4-(5-bromo-2-hydroxybenzoylamino)-2-fluorophenyl]piperidin-4-yl}carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms

Herein, we describe the design, synthesis, and structure-activity relationships of a series of unique 4-(1H-pyrazol-4-yl)-pyrimidin-2-amine derivatives that selectively inhibit Janus kinase 2 (JAK2) and FLT3 kinases. These screening cascades revealed that 18e was a preferred compound, with IC50 values of 0.7 and 4 nM for JAK2 and FLT3, respectively. Moreover, 18e was a potent JAK2 inhibitor with 37-fold and 56-fold selectivity over JAK1 and JAK3, respectively, and possessed an excellent selectivity profile over the other 100 representative kinases. In a series of cytokine-stimulated cell-based assays, 18e exhibited a higher JAK2 selectivity over other JAK isoforms. The oral administration of 60 mg/kg of 18e could significantly inhibit tumor growth, with a tumor growth inhibition rate of 93 and 85% in MV4-11 and SET-2 xenograft models, respectively. Additionally, 18e showed an excellent bioavailability (F = 58%), a suitable half-life time (T1/2 = 4.1 h), a satisfactory metabolic stability, and a weak CYP3A4 inhibitory activity, suggesting that 18e might be a potential drug candidate for JAK2-driven myeloproliferative neoplasms and FLT3-internal tandem duplication-driven acute myelogenous leukemia.

NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME

The present invention relates to a novel 2,6-substituted-3-nitropyridine derivative compound, a method for preparing the same, and a pharmaceutical composition including the same for prevention and treatment of osteoporosis. The 2,6-substituted-3-nitropyr

NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME

The present invention relates to a novel 2,6-substituted-3-nitropyridine derivative compound, a method for preparing the same, and a pharmaceutical composition including the same for prevention and treatment of osteoporosis. The 2,6-substituted-3-nitropyr

N-(3,4-disubstituted phenyl) salicylamide derivatives

A compound represented by the following formula (I) or a salt thereof: wherein R1, R2, R3 and R4 represent hydrogen atom, a halogen atom, cyano group, nitro group, a C1-4 alkyl group, a halogenated C